Overview
The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product).
This LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).
Eligibility
Inclusion Criteria:
- Provided informed consent for the LTFU study
- Received at least 1 infusion of KYV-101 as part of a previous KYV-101 parent treatment protocol
Exclusion Criteria:
- Not applicable